Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington's disease

Neurobiology of Disease

Volumn 46, Issue 2, 2012, Pages 351-361

  Jia, Haiqun ^a   Pallos, Judit ^b   Jacques, Vincent ^c   Lau, Alice ^d   Tang, Bin ^a   Cooper, Andrew ^c   Syed, Adeela ^b   Purcell, Judith ^b   Chen, Yi ^c   Sharma, Shefali ^c   Sangrey, Gavin R ^e   Darnell, Shayna B ^e   Plasterer, Heather ^c   Sadri Vakili, Ghazaleh ^e   Gottesfeld, Joel M ^a   Thompson, Leslie M ^d   Rusche, James R ^c   Marsh, J Lawrence ^b   Thomas, Elizabeth A ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c REPLIGEN CORPORATION   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Chromatin; Disease; Epigenetic; Gene expression; Neurodegenerative; Striatum; Therapeutic

Indexed keywords

HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 7; HISTONE DEACETYLASE INHIBITOR; HUNTINGTIN; PHOSPHOPROTEIN DARPP 32; POLYGLUTAMINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL NUCLEUS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CORPUS STRIATUM; CYTOPLASM; DROSOPHILA MELANOGASTER; DRUG POTENCY; DRUG STRUCTURE; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUNTINGTON CHOREA; IC 50; MOUSE; NERVE DEGENERATION; NONHUMAN; PPP1R1B GENE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DROSOPHILA MELANOGASTER; DRUG DELIVERY SYSTEMS; HCT116 CELLS; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; HUNTINGTON DISEASE; MICE; MICE, INBRED C57BL; MICE, INBRED CBA; MICE, TRANSGENIC; PEPTIDES; PHENOTYPE;

EID: 84862819579     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2012.01.016     Document Type: Article

References (42)

1. Abel T., Zukin R.S. Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders. Curr. Opin. Pharmacol. 2008, 8:57-64.
2. Adcock I.M., Ford P., Ito K., Barnes P.J. Epigenetics and airways disease. Respir. Res. 2006, 7:21.
3. Bardai F.H., D'Mello S.R. Selective toxicity by HDAC3 in neurons: regulation by Akt and GSK3beta. J. Neurosci. 2011, 31:1746-1751.
4. Blander G., Guarente L. The Sir2 family of protein deacetylases. Annu. Rev. Biochem. 2004, 73:417-435.
5. Bradner J.E., West N., Grachan M.L., Greenberg E.F., et al. Chemical phylogenetics of histone deacetylases. Nat. Chem. Biol. 2011, 6:238-243.
6. Chou C.J., Herman D.M., Gottesfeld J.M. Pimelic diphenylamide 106 is a slow, tight-binding inhibitor of class I histone deacetylases. J. Biol. Chem. 2008, 283:35402-35409.
7. Cui L., Jeong H., Borovecki F., Parkhurst C.N., et al. Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 2006, 127:59-69.
8. Desplats P.A., Kass K.E., Gilmartin T., Stanwood G.D., et al. Selective deficits in the expression of striatal-enriched mRNAs in Huntington's disease. J. Neurochem. 2006, 96:743-757.
9. Ferrante R.J., Kubilus J.K., Lee J., Ryu H., et al. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J. Neurosci. 2003, 23:9418-9427.
10. Ferrante R.J., Ryu H., Kubilus J.K., D'Mello S., et al. Chemotherapy for the brain: the antitumor antibiotic mithramycin prolongs survival in a mouse model of Huntington's disease. J. Neurosci. 2004, 24:10335-10342.
11. Fischle W., Dequiedt F., Hendzel M.J., Guenther M.G., et al. Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. Mol. Cell 2002, 9:45-57.
12. Freiman R.N., Tjian R. Neurodegeneration. A glutamine-rich trail leads to transcription factors. Science 2002, 296:2149-2150.
13. Gao L., Cueto M.A., Asselbergs F., Atadja P. Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. J. Biol. Chem. 2002, 277:25748-25755.
14. Gardian G., Browne S.E., Choi D.K., Klivenyi P., et al. Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease. J. Biol. Chem. 2005, 280:556-563.
15. Group HsDCR A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 1993, 72:971-983.
16. Hahnen E., Hauke J., Trankle C., Eyupoglu I.Y., et al. Histone deacetylase inhibitors: possible implications for neurodegenerative disorders. Expert Opin. Investig. Drugs 2008, 17:169-184.
17. Hildmann C., Riester D., Schwienhorst A. Histone deacetylases - an important class of cellular regulators with a variety of functions. Appl. Microbiol. Biotechnol. 2007, 75:487-497.
18. Hockly E., Richon V.M., Woodman B., Smith D.L., et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:2041-2046.
19. Kazantsev A.G., Thompson L.M. Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat. Rev. Drug Discov. 2008, 7:854-868.
20. Kornberg R.D., Lorch Y. Twenty-five years of the nucleosome, fundamental particle of the eukaryote chromosome. Cell 1999, 98:285-294.
21. Lee J.M., Ivanova E.V., Seong I.S., Cashorali T., et al. Unbiased gene expression analysis implicates the huntingtin polyglutamine tract in extra-mitochondrial energy metabolism. PLoS Genet 2007, 3:e135.
22. Mangiarini L., Sathasivam K., Seller M., Cozens B., et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996, 87:493-506.
23. Marsh J.L., Lukacsovich T., Thompson L.M. Animal models of polyglutamine diseases and therapeutic approaches. J. Biol. Chem. 2009, 284:7431-7435.
24. McCampbell A., Taye A.A., Whitty L., Penney E., et al. Histone deacetylase inhibitors reduce polyglutamine toxicity. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:15179-15184.
25. McQuown SC, Barrett RM, Matheos DP, Post RJ, et al. 2011. HDAC3 is a critical negative regulator of long-term memory formation. J Neurosci 31:764-74.
26. Morrison B.E., Majdzadeh N., D'Mello S.R. Histone deacetylases: focus on the nervous system. Cell. Mol. Life Sci. 2007, 64:2258-2269.
27. Nucifora F.C., Sasaki M., Peters M.F., Huang H., et al. Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science 2001, 291:2423-2428.
28. Okazawa H. Polyglutamine diseases: a transcription disorder?. Cell Mol Life Sci 2003, 60:1427-1439.
29. Pallos J., Bodai L., Lukacsovich T., Purcell J.M., et al. Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington's disease. Hum. Mol. Genet. 2008, 17:3767-3775.
30. Ryu H., Lee J., Hagerty S.W., Soh B.Y., et al. ESET/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington's disease. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:19176-19181.
31. Sadri-Vakili G., Bouzou B., Benn C.L., Kim M.O., et al. Histones associated with downregulated genes are hypo-acetylated in Huntington's disease models. Hum. Mol. Genet. 2007, 16:1293-1306.
32. Sandi C., Pinto R.M., Al-Mahdawi S., Ezzatizadeh V., et al. Prolonged treatment with pimelic o-aminobenzamide HDAC inhibitors ameliorates the disease phenotype of a Friedreich ataxia mouse model. Neurobiol. Dis. 2011, 42:496-505.
33. Stack E.C., Del Signore S.J., Luthi-Carter R., Soh B.Y., et al. Modulation of nucleosome dynamics in Huntington's disease. Hum. Mol. Genet. 2007, 16:1164-1175.
34. Steffan J.S., Bodai L., Pallos J., Poelman M., et al. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 2001, 413:739-743.
35. Sugars K.L., Rubinsztein D.C. Transcriptional abnormalities in Huntington disease. Trends Genet. 2003, 19:233-238.
36. Thomas E.A. Striatal specificity of gene expression dysregulation in Huntington's disease. J. Neurosci. Res. 2006, 84:1151-1164.
37. Thomas E.A., Coppola G., Desplats P.A., Tang B., et al. The HDAC inhibitor, 4b, ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:15564-15569.
38. Trettel F., Rigamonti D., Hilditch-Maguire P., Wheeler V.C., et al. Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells. Hum. Mol. Genet. 2000, 9:2799-2809.
39. Valencia A., Reeves P.B., Sapp E., Li X., et al. Mutant huntingtin and glycogen synthase kinase 3-beta accumulate in neuronal lipid rafts of a presymptomatic knock-in mouse model of Huntington's disease. J. Neurosci. Res. 2011, 88:179-190.
40. Xu W.S., Parmigiani R.B., Marks P.A. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007, 26:5541-5552.
41. Xu C., Soragni E., Chou C.J., Herman D., et al. Chemical probes identify a role for histone deacetylase 3 in Friedreich's ataxia gene silencing. Chem. Biol. 2009, 16:980-989.
42. Zhai W., Jeong H., Cui L., Krainc D., et al. In vitro analysis of huntingtin-mediated transcriptional repression reveals multiple transcription factor targets. Cell 2005, 123:1241-1253.